Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential Target
Open Access
- 5 March 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (3) , e0001722
- https://doi.org/10.1371/journal.pone.0001722
Abstract
Lung cancer causes approximately 1.2 million deaths per year worldwide, and non-small cell lung cancer (NSCLC) represents 85% of all lung cancers. Understanding the molecular events in non-small cell lung cancer (NSCLC) is essential to improve early diagnosis and treatment for this disease. In an attempt to identify novel NSCLC related genes, we performed a genome-wide screening of chromosomal copy number changes affecting gene expression using microarray based comparative genomic hybridization and gene expression arrays on 32 radically resected tumor samples from stage I and II NSCLC patients. An integrative analysis tool was applied to determine whether chromosomal copy number affects gene expression. We identified a deletion on 14q32.2-33 as a common alteration in NSCLC (44%), which significantly influenced gene expression for HSP90, residing on 14q32. This deletion was correlated with better overall survival (P = 0.008), survival was also longer in patients whose tumors had low expression levels of HSP90. We extended the analysis to three independent validation sets of NSCLC patients, and confirmed low HSP90 expression to be related with longer overall survival (P = 0.003, P = 0.07 and P = 0.04). Furthermore, in vitro treatment with an HSP90 inhibitor had potent antiproliferative activity in NSCLC cell lines. We suggest that targeting HSP90 will have clinical impact for NSCLC patients.Keywords
This publication has 35 references indexed in Scilit:
- Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesPublished by Elsevier ,2006
- A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung CancerPLoS Medicine, 2006
- Heat Shock Protein 90: A Unique Chemotherapeutic TargetSeminars in Oncology, 2006
- Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor ReceptorsCancer Research, 2006
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic FeaturesClinical Cancer Research, 2005
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Chromosomal imbalances in human lung cancerOncogene, 2002
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002